X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare JUBILANT LIFE SCIENCES with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs PIRAMAL ENTERPRISES - Comparison Results

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES PIRAMAL ENTERPRISES JUBILANT LIFE SCIENCES/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 14.6 8.2 176.8% View Chart
P/BV x 4.3 1.5 291.6% View Chart
Dividend Yield % 0.4 1.1 38.2%  

Financials

 JUBILANT LIFE SCIENCES   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-14
PIRAMAL ENTERPRISES
Mar-18
JUBILANT LIFE SCIENCES/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs1873,083 6.1%   
Low Rs651,902 3.4%   
Sales per share (Unadj.) Rs364.3589.7 61.8%  
Earnings per share (Unadj.) Rs6.8284.0 2.4%  
Cash flow per share (Unadj.) Rs24.5310.5 7.9%  
Dividends per share (Unadj.) Rs3.0025.00 12.0%  
Dividend yield (eoy) %2.41.0 237.5%  
Book value per share (Unadj.) Rs164.91,467.0 11.2%  
Shares outstanding (eoy) m159.28180.27 88.4%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x0.34.2 8.2%   
Avg P/E ratio x18.48.8 209.7%  
P/CF ratio (eoy) x5.18.0 64.0%  
Price / Book Value ratio x0.81.7 45.0%  
Dividend payout %43.88.8 497.9%   
Avg Mkt Cap Rs m20,061449,332 4.5%   
No. of employees `0006.26.8 90.4%   
Total wages/salary Rs m11,05219,881 55.6%   
Avg. sales/employee Rs Th9,383.015,535.6 60.4%   
Avg. wages/employee Rs Th1,786.92,905.4 61.5%   
Avg. net profit/employee Rs Th176.37,482.5 2.4%   
INCOME DATA
Net Sales Rs m58,034106,310 54.6%  
Other income Rs m1912,595 7.3%   
Total revenues Rs m58,224108,906 53.5%   
Gross profit Rs m5,78651,599 11.2%  
Depreciation Rs m2,8124,773 58.9%   
Interest Rs m3,23729,783 10.9%   
Profit before tax Rs m-7219,638 -0.4%   
Minority Interest Rs m-2862,801 -10.2%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m2,1450-   
Tax Rs m696-28,764 -2.4%   
Profit after tax Rs m1,09051,203 2.1%  
Gross profit margin %10.048.5 20.5%  
Effective tax rate %-965.9-146.5 659.4%   
Net profit margin %1.948.2 3.9%  
BALANCE SHEET DATA
Current assets Rs m29,280118,154 24.8%   
Current liabilities Rs m38,912462,260 8.4%   
Net working cap to sales %-16.6-323.7 5.1%  
Current ratio x0.80.3 294.4%  
Inventory Days Days8427 317.5%  
Debtors Days Days5147 108.9%  
Net fixed assets Rs m55,712113,727 49.0%   
Share capital Rs m155361 42.9%   
"Free" reserves Rs m20,968264,093 7.9%   
Net worth Rs m26,265264,454 9.9%   
Long term debt Rs m17,169242,206 7.1%   
Total assets Rs m88,606726,834 12.2%  
Interest coverage x1.01.7 58.9%   
Debt to equity ratio x0.70.9 71.4%  
Sales to assets ratio x0.70.1 447.8%   
Return on assets %4.911.1 43.8%  
Return on equity %4.219.4 21.4%  
Return on capital %11.610.3 112.2%  
Exports to sales %37.80-   
Imports to sales %16.50-   
Exports (fob) Rs m21,933NA-   
Imports (cif) Rs m9,567NA-   
Fx inflow Rs m22,00415,110 145.6%   
Fx outflow Rs m11,7494,298 273.4%   
Net fx Rs m10,25510,813 94.8%   
CASH FLOW
From Operations Rs m8,026-159,666 -5.0%  
From Investments Rs m-1,744-17,677 9.9%  
From Financial Activity Rs m-4,447186,503 -2.4%  
Net Cashflow Rs m1,8349,364 19.6%  

Share Holding

Indian Promoters % 45.6 52.9 86.2%  
Foreign collaborators % 3.5 0.0 -  
Indian inst/Mut Fund % 8.7 4.0 217.5%  
FIIs % 21.2 26.6 79.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 16.5 127.9%  
Shareholders   23,815 93,274 25.5%  
Pledged promoter(s) holding % 15.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   VENUS REMEDIES  ORCHID PHARMA LTD  NOVARTIS  J.B.CHEMICALS  SHASUN PHARMA  

Compare JUBILANT LIFE SCIENCES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Over 260 Points Down; TCS & Infosys Top Losers(12:30 pm)

Stock markets in India are presently trading lower, tracking weakness in their global peers. Among the sectoral indices, IT stocks and metal stocks are witnessing maximum selling pressure.

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY19); Net Profit Up 67.2% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 67.2% YoY). Sales on the other hand came in at Rs 23 bn (up 38.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY19); Net Profit Up 59.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 59.3% YoY). Sales on the other hand came in at Rs 31 bn (up 24.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY19); Net Profit Down 152.5% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 1 bn (down 152.5% YoY). Sales on the other hand came in at Rs 29 bn (up 28.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY19); Net Profit Up 39.4% (Quarterly Result Update)

Jul 31, 2018 | Updated on Jul 31, 2018

For the quarter ended June 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 39.4% YoY). Sales on the other hand came in at Rs 21 bn (up 30.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY18); Net Profit Up 1.4% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 1.4% YoY). Sales on the other hand came in at Rs 23 bn (up 37.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Nov 21, 2018 02:57 PM

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES - ALKEM LABORATORIES COMPARISON

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS